Nastoupil: Spectrum: Honoraria; Janssen: Research Funding; Novartis: Honoraria; Merck: Honoraria, Research Funding; Juno: Honoraria; Gilead: Honoraria; Karus: Research Funding; TG Therappeutics: Research Funding; Genentech: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Champlin:Sanofi: Research Funding; Otsuka: Research Funding. Neelapu:Novartis: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; Acerta: Research Funding; Merck: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Poseida: Research Funding; Cellectis: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karus: Research Funding; Unum Therapeutics: Membership on an entity's Board of Directors or advisory committees. Fowler:Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy, Research Funding. Wang:MoreHealth: Consultancy; Kite Pharma: Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno: Research Funding; Acerta Pharma: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Research Funding; Dava Oncology: Honoraria; Pharmacyclics: Honoraria, Research Funding; Novartis: Research Funding.